생백신 시장 규모, 점유율 및 성장 분석 : 백신 유형별, 백신 개발 방법별, 투여 방법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Live Attenuated Vaccines Market size was valued at USD 23.36 Billion in 2024 and is poised to grow from USD 25.72 Billion in 2025 to USD 55.52 Billion by 2033, growing at a CAGR of 10.1% during the forecast period (2026-2033).

The global live attenuated vaccines market is driven by biologically engineered pathogens that maintain limited replicative capacity, offering lasting immunity with fewer doses. This is vital for preventing diseases such as measles, rotavirus, and oral polio, ultimately reducing mortality and healthcare costs. Key growth factors include the rising middle-class population in emerging economies, which boosts both government vaccine procurement and private sector investments. Innovations in delivery technologies, particularly those enhancing thermostability and administration ease, further accelerate market growth. The integration of AI in strain selection, genetic modifications, and immune response predictions expedites the vaccine development process, enabling a quicker transition from concept to pre-clinical testing. Overall, this dynamic landscape promotes investment in R&D, fostering faster revenue cycles and attracting venture capital interest.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Live Attenuated Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Live Attenuated Vaccines Market Segments Analysis

The global live attenuated vaccines market is segmented by vaccine type, vaccine development method, mode of administration, end user and region. Based on vaccine type, the market is segmented into Viral Vaccines and Bacterial Vaccines. Based on vaccine development method, the market is segmented into Tissue Culture, Embryonated Eggs and Live Animals. Based on mode of administration, the market is segmented into Injectable, Oral and Intranasal. Based on end user, the market is segmented into Hospitals & Clinics, Government Immunization Programs and Travel Medicine Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Live Attenuated Vaccines Market

The increasing awareness among the public regarding vaccine-preventable diseases, combined with a strong emphasis on achieving herd immunity, has led both healthcare providers and governments to prioritize live attenuated vaccine initiatives. This commitment fosters greater funding for research and development, enhances production capabilities, and streamlines distribution channels, ultimately broadening access to these vital vaccines across diverse populations. As health authorities increasingly adopt preventive healthcare strategies, the demand for safe and effective immunization options continues to rise. This growing demand not only expands the market for live attenuated vaccines but also encourages developers to innovate new formulations designed to address emerging pathogen threats while maintaining proven efficacy for global health security.

Restraints in the Global Live Attenuated Vaccines Market

The Global Live Attenuated Vaccines market faces significant challenges due to regulatory constraints and approval delays. Stringent safety and efficacy standards mandated by health authorities can prolong the clinical trial process, resulting in higher development costs and creating uncertainty for potential investors. This scenario often dissuades smaller companies from entering the market. Additionally, disparities in regulatory frameworks across different regions can fragment global rollout strategies, slowing the introduction of new products to patients and ultimately hindering market growth. The requirement for comprehensive post-marketing surveillance further compounds operational pressures, leading to additional commercialization delays and impacting overall market dynamics.

Market Trends of the Global Live Attenuated Vaccines Market

The Global Live Attenuated Vaccines market is witnessing a significant shift towards personalized immunization platforms driven by advancements in genomics and data analytics. Manufacturers are increasingly leveraging population-level immune signatures and strain-selection algorithms to create tailored vaccines that cater to specific demographic and epidemiological profiles. This personalized approach not only enhances efficacy perceptions and minimizes adverse events but also aligns with public health initiatives aimed at increasing vaccination uptake, positioning companies as innovators in the field. Consequently, this trend is expected to diversify revenue streams through strategic licensing agreements, reinforcing the long-term sustainability of firms within the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Live Attenuated Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Viral Vaccines
  • MMR (Measles)
  • Mumps
  • Rubella
  • Varicella (Chickenpox)
  • Rotavirus Vaccine
  • Oral Polio Vaccine (OPV)
  • Yellow Fever Vaccine
  • Influenza (Live Attenuated)
• Bacterial Vaccines
  • BCG (Tuberculosis)
  • Oral Typhoid Vaccine
  • Oral Cholera Vaccine

Global Live Attenuated Vaccines Market Size by Vaccine Development Method & CAGR (2026-2033)

• Market Overview
• Tissue Culture
• Embryonated Eggs
• Live Animals

Global Live Attenuated Vaccines Market Size by Mode of Administration & CAGR (2026-2033)

• Market Overview
• Injectable
• Oral
• Intranasal

Global Live Attenuated Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Government Immunization Programs
• Travel Medicine Clinics

Global Live Attenuated Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Vaccine Development Method, Mode of Administration, End User)
  • US
  • Canada
• Europe (Vaccine Type, Vaccine Development Method, Mode of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Vaccine Development Method, Mode of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Vaccine Development Method, Mode of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Vaccine Development Method, Mode of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK Bioscience Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paxvax Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OvaScience Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Institute of Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Institute of Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations